Pharmacotherapy of relapsed metastatic testicular cancer

Expert Opinion on Pharmacotherapy
C KollmannsbergerC Bokemeyer

Abstract

Patients with metastatic testicular cancer exhibit an excellent prognosis. However, the outcome for patients with relapse after cisplatin-based chemotherapy remains unsatisfactory. Several larger studies have been recently published. To review the treatment of patients with testicular cancer after failure of first-line chemotherapy. A literature search was performed for studies investigating therapies for relapsed testicular cancer. The prognosis of patients relapsing after first-line cisplatin-based chemotherapy has improved with multimodality therapy, including conventional and high-dose chemotherapy, surgery and radiation. Prognostic factors are increasingly used to guide treatment intensity. High-dose chemotherapy has become an accepted treatment option, in particular in patients with poor risk factors at relapse. The outcome of patients with multiply relapsed or cisplatin-refractory disease remains particularly poor. Treatment of relapsed patients requires a close cooperation of medical oncologists, urologists, surgeons and radiation oncologists with extensive experience in this disease.

References

Feb 20, 1992·International Journal of Cancer. Journal International Du Cancer·Y KanoY Miura
Sep 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A HarstrickC Bokemeyer
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H Einhorn
Feb 1, 1990·American Journal of Clinical Oncology·P HoskinsN Murray
Sep 1, 1990·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HarstrickH Poliwoda
Jul 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C R NicholsS N Wolff
May 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D HainsworthF A Greco
Apr 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerS D Williams
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerP Fischer
May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BanielL H Einhorn
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B R MurphyL H Einhorn
Mar 1, 1993·British Journal of Cancer·D JosefsenS D Fosså
Jan 1, 1995·Investigational New Drugs·H S PucR J Motzer
Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BeyerW Siegert
Jan 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BokemeyerH J Schmoll
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K D MillerL H Einhorn
Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A McCaffreyR J Motzer
Jun 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J T HartmannC Bokemeyer
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerL H Einhorn
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H EinhornS D Williams
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C BokemeyerL Kanz
Jun 11, 1999·The American Journal of Pathology·Q TianC A Moskaluk
Aug 12, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J ShamashM Williams
Dec 10, 1999·Seminars in Surgical Oncology·C R Nichols
Dec 22, 1999·International Journal of Cancer. Journal International Du Cancer·C Nichols, R Maziarz
Jan 13, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C KollmannsbergerC Bokemeyer

❮ Previous
Next ❯

Citations

May 17, 2011·Hematology/oncology Clinics of North America·Christine M Veenstra, David J Vaughn
Jul 28, 2011·International Journal of Andrology·D KoychevF Honecker
Dec 30, 2014·Andrology·C Jacobsen, F Honecker
Nov 15, 2014·Journal of Cancer Research and Clinical Oncology·Christoph OingKarin Oechsle
Dec 15, 2015·Lancet·Ewa Rajpert-De MeytsCarsten Bokemeyer
Mar 9, 2018·Expert Review of Anticancer Therapy·Christoph OingCarsten Bokemeyer
Jul 28, 2016·World Journal of Urology·Christoph OingCarsten Bokemeyer
Nov 22, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C KollmannsbergerC Nichols

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Xavier Garcia-del-MuroJosep R Germá-Lluch
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
F P HarmersJ P Neijt
© 2022 Meta ULC. All rights reserved